Self-devaluation of Antibiotics as a Side Effect of Their Use
Article Sidebar
Main Article Content
Abstract
Despite their long history of use, antibiotics remain the primary treatment for inflammatory diseases. However, it is often overlooked that these drugs are capable of killing only certain types of bacteria and do not directly affect inflammatory mechanisms. Moreover, long-term antimicrobial therapy leads to the development of side effects, including changes in the etiology of acute pneumonia. The prolonged and methodical eradication of common pneumonia pathogens forces nature to gradually replace them with agents unrelated to the spectrum of antimicrobial activity. It is this circumstance, and not microbial resistance, as is currently believed, that is the main reason for the decline in antibiotic effectiveness. This conclusion is supported by the prevalence of viral forms of pneumonia, while only a few resistant strains of pathogens are identified among the small number of bacterial infections. This latter statement indicates the need to reconsider the concept of disease and remove antibiotics from the list of miracle cures.
Article Details
Copyright (c) 2026 Klepikov I.
This work is licensed under a Creative Commons Attribution 4.0 International License.
1. Abraham EP, Chain E. An enzyme from bacteria can destroy penicillin. Rev Infect Dis. 1988;10(4):677–678. Available from: https://pubmed.ncbi.nlm.nih.gov/3055168/
2. Rammelkamp T. Resistance of Staphylococcus aureus to the action of penicillin. Exp Biol Med. 1942;51:386–389. Available from: https://doi.org/10.3181/00379727-51-13986
3. Avery OT, Chickering HT, Cole RI, Dochez AR. Acute lobar pneumonia: prevention and serum treatment. Monographs of the Rockefeller Institute for Medical Research. New York: Rockefeller Institute for Medical Research; 1917. Available from: https://digitalcommons.rockefeller.edu/cgi/viewcontent.cgi?article=1004&context=monographs-rockefeller-institute
4. Cole RI. Acute pulmonary infections. De La Mar Lectures. Baltimore: Williams & Wilkins; 1927–1928.
5. Sutliff WD, Finland M. The significance of the newly classified types of pneumococci in disease: types IV to XX inclusive. JAMA. 1933;101:1289–1295. Available from: https://jamanetwork.com/journals/jama/article-abstract/245616
6. Heffron R. Pneumonia, with special reference to pneumococcus lobar pneumonia. Cambridge: Harvard University Press; 1939.
7. Small JT. A short history of the pneumococcus with special reference to lobar pneumonia. Edinb Med J. 1948;55(3):129–141.
8. MRSA history timeline: the first half-century, 1959–2009. Chicago: The University of Chicago Medical Center; 2010. Available from: https://doi.org/10.1093/jac/dkr437
9. Aminov RI. A brief history of the antibiotic era: lessons learned and challenges for the future. Front Microbiol. 2010;1:134. Available from: https://doi.org/10.3389/fmicb.2010.00134
10. Kyriazopoulou E, Karageorgos A, Liaskou-Antoniou L, et al. BioFire FilmArray pneumonia panel for severe lower respiratory tract infections: subgroup analysis of a randomized clinical trial. Infect Dis Ther. 2021;10:1437–1449. Available from: https://doi.org/10.1007/s40121-021-00459-x
11. Pickens CI, Gao CA, Morales-Nebreda L, Wunderink RG. Microbiology of severe community-acquired pneumonia and the role of rapid molecular techniques. Semin Respir Crit Care Med. 2024;45(2):158–168. Available from: https://doi.org/10.1055/s-0043-1777770
12. Ling L, Lai CKC, Rhee C. Bacterial multiplex polymerase chain reaction tests for the diagnosis and management of pneumonia: ready for prime time? Thorax. 2025;80:862–872. Available from: https://doi.org/10.1136/thorax-2024-222297
13. Podolsky SH. The changing fate of pneumonia as a public health concern in 20th-century America and beyond. Am J Public Health. 2005 Dec;95(12):2144–2154. Available from: https://doi.org/10.2105/ajph.2004.048397
14. Metlay JP, Waterer GW, Long AC, Anzueto A, Brozek J, Crothers K, et al. Diagnosis and treatment of adults with community-acquired pneumonia: an official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med. 2019 Oct 1;200(7):e45–e67. Available from: https://doi.org/10.1164/rccm.201908-1581st
15. Martin-Loeches I, Torres A, Nagavci B, Aliberti S, Antonelli M, Bassetti M, et al. ERS/ESICM/ESCMID/ALAT guidelines for the management of severe community-acquired pneumonia. Intensive Care Med. 2023;49:615–632. Available from: https://doi.org/10.1007/s00134-023-07033-8
16. Gadsby NJ, Musher DM. The microbial etiology of community-acquired pneumonia in adults: from classical bacteriology to host transcriptional signatures. Clin Microbiol Rev. 2022;35:e00015-22. Available from: https://doi.org/10.1128/cmr.00015-22
17. Sirota SB, Bender RG, Villanueva Dominguez RM, Movo A, Swetschinski LR, Araki DT, et al. Global burden of lower respiratory infections and aetiologies, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023. Lancet Infect Dis. 2025. Available from: https://doi.org/10.1016/s1473-3099(25)00689-9
18. World Health Organization. Revised global burden of disease 2002 estimates. Geneva: World Health Organization; 2004. Available from: http://www.who.int/healthinfo/global_burden_disease/estimates_regional_2002_revised/en/
19. Ruuskanen O, Lahti E, Jennings LC, Murdoch DR. Viral pneumonia. Lancet. 2011;377(9773):1264–1275. Available from: https://doi.org/10.1016/s0140-6736(10)61459-6
20. Leiter RE. Reentry. N Engl J Med. 2020 Oct 14. Available from: https://doi.org/10.1056/nejmp2027447
21. Rosenquist JN. The stress of Bayesian medicine—uncomfortable uncertainty in the face of COVID-19. N Engl J Med. 2021;384:7–9. Available from: https://doi.org/10.1056/nejmp2018857
22. Salisbury H. Helen Salisbury: what might we learn from the COVID-19 pandemic? BMJ. 2020;368:m1087. Available from: https://doi.org/10.1136/bmj.m1087
23. Oliver D. David Oliver: conveyor belt medicine. BMJ. 2020;368:m162. Available from: https://doi.org/10.1136/bmj.m162
24. Gostin LO, Gronvall GK. The origins of COVID-19—why it matters (and why it doesn’t). N Engl J Med. 2023;388:2305–2308. Available from: https://doi.org/10.1056/nejmp2305081
25. Editors. Dying in a leadership vacuum. N Engl J Med. 2020 Oct 8;383(15):1479–1480. Available from: https://doi.org/10.1056/nejme2029812
26. Huttner BD, Catho G, Pano-Pardo JR, Pulcini C, Schouten J. COVID-19: don't neglect antimicrobial stewardship principles! Clin Microbiol Infect. 2020;26(7):808–810. Available from: https://doi.org/10.1016/j.cmi.2020.04.024
27. Beovic B, Doušak M, Ferreira-Coimbra J, Nadrah K, Rubulotta F, Belliato M, et al. Antibiotic use in patients with COVID-19: a ‘snapshot’ Infectious Diseases International Research Initiative (ID-IRI) survey. J Antimicrob Chemother. 2020;dkaa326. Available from: https://doi.org/10.1093/jac/dkaa326
28. Rawson TM, Moore LSP, Zhu N, Ranganathan N, Skolimowska K, Gilchrist M, et al. Bacterial and fungal co-infection in individuals with coronavirus: a rapid review to support COVID-19 antimicrobial prescribing. Clin Infect Dis. 2020;ciaa530. Available from: https://doi.org/10.1093/cid/ciaa530
29. Hsu J. AI discovers a new class of antibiotics to kill resistant bacteria. New Sci. 2024 Jan 6;261(3472):12. Available from: https://doi.org/10.1016/S0262-4079(24)00011-3
30. Malinis M, Abbo L, Vazquez JA, Ostrosky-Zeichner L. Community-acquired pneumonia: a US perspective on the guideline gap. J Antimicrob Chemother. 2024;79(5):959–961. Available from: https://doi.org/10.1093/jac/dkae050
31. Khan MA, Bajwa A, Hussain ST. Pneumonia: recent updates on diagnosis and treatment. Microorganisms. 2025;13(3):522. Available from: https://doi.org/10.3390/microorganisms13030522
32. Besteman SB, Bogaert D, Bont L, Mejias A, Ramilo O, Weinberger DM, et al. Interactions between respiratory syncytial virus and Streptococcus pneumoniae in the pathogenesis of childhood respiratory infections: a systematic review. Lancet Respir Med. 2024;12(11):915–932. Available from: https://doi.org/10.1016/s2213-2600(24)00148-6
33. Lansbury L, McKeever TM, Lawrence H, Pick H, Baskaran V, Edwards-Pritchard R, et al. Pneumococcal pneumonia trends in adults hospitalised with community-acquired pneumonia over 10 years (2013–2023) and the role of serotype 3. Thorax. 2025;80:86–96. Available from: https://doi.org/10.1136/thorax-2024-221976
34. Olarte L, Musher DM, Rodriguez-Barradas MC. Higher-valent pneumococcal conjugate vaccines—perspective for 2026. JAMA Intern Med. 2025;185(12):1493–1494. Available from: https://doi.org/10.1001/jamainternmed.2025.5436
35. Pan D, Nielsen E, Chung S, Niederman MS. Management of pneumonia in the critically ill. Minerva Med. 2023;114:667–682. Available from: https://doi.org/10.23736/s0026-4806.22.08467-1
36. Oliveira E Silva PG, Cerqueira Batista Filho LA, Ismael PF, Victoria VES, Alexandre TM, Larissa SM. Community-acquired pneumonia: epidemiology, diagnosis, prognostic severity scales, and new therapeutic options. Medwave. 2023;23(11):e2719. Available from: https://doi.org/10.5867/medwave.2023.11.2719
37. Palomeque A, Cilloniz C, Soler-Comas A, Canseco-Ribas J, Rovira-Ribalta N, Motos A, et al. A review of the value of point-of-care testing for community-acquired pneumonia. Expert Rev Mol Diagn. 2024;1–14. Available from: https://doi.org/10.1080/14737159.2024.2391027
38. Long ME, Mallampalli RK, Horowitz JC. Pathogenesis of pneumonia and acute lung injury. Clin Sci (Lond). 2022 May 27;136(10):747–769. Available from: https://doi.org/10.1042/cs20210879
39. Rabin EE, Walter JM, Wunderink RG, Qi C, Pickens CI. Clinical significance of culture-negative, PCR-positive bronchoalveolar lavage results in severe pneumonia. ERJ Open Res. 2023 Nov 13;9(6):00343-2023. Available from: https://doi.org/10.1183/23120541.00343-2023
40. World Health Organization. Antimicrobial resistance. 2021 Nov 17. Available from: https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance
41. Sakamoto Y, Yamauchi Y, Jo T, Michihata N, Hasegawa W, Takeshima H, et al. In-hospital mortality associated with community-acquired pneumonia due to methicillin-resistant Staphylococcus aureus: a matched-pair cohort study. BMC Pulm Med. 2021;21:345. Available from: https://doi.org/10.1186/s12890-021-01713-1
42. Ding H, Mang NS, Loomis J, Ortwine JK, Wei W, O’Connell EJ, Shah NJ, Prokesch BC. Incidence of drug-resistant pathogens in community-acquired pneumonia at a safety net hospital. Microbiol Spectr. 2024;12:e00792-24. Available from: https://doi.org/10.1128/spectrum.00792-24
43. Gohil SK, Septimus E, Kleinman K, Avery TR, Varma N, Sands KE, et al. Initial antibiotic selection strategy and subsequent antibiotic use—insights from the INSPIRE trials. JAMA. 2025;334(12):1107–1109. Available from: https://doi.org/10.1001/jama.2025.11256
44. Aubry-Damon H, Grenet K, Ndiaye-Sall P, Che D, Corderio E, Bougnoux M, Rigaud E, Le Strat Y, Lemanissier V, Andremont A, et al. Antimicrobial resistance in commensal flora of pig farmers. Emerg Infect Dis. 2004;10:873–879. Available from: https://doi.org/10.3201/eid1005.030735
45. Albrich WC, Harbarth S. Health-care workers: source, vector, or victim of MRSA? Lancet Infect Dis. 2008;8:289–301. Available from: https://doi.org/10.1016/s1473-3099(08)70097-5
46. Graveland H, Wagenaar JA, Heesterbeek H, Mevius D, van Duijkeren E, Heederik D. Methicillin-resistant Staphylococcus aureus ST398 in veal calf farming: human MRSA carriage related with animal antimicrobial usage and farm hygiene. PLoS One. 2010;5:e10990. Available from: https://doi.org/10.1371/journal.pone.0010990
47. Serwecińska L. Antimicrobials and antibiotic-resistant bacteria: a risk to the environment and to public health. Water. 2020;12(12):3313. Available from: https://doi.org/10.3390/w12123313
48. Thara M. Antibiotic stewardship. Medicon Med Sci. 2024;6(3):1–2. Available from: https://doi.org/10.55162/MCMS.06.196